Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.65 |
| ▸ | RARG | P13631 | 17/20 | 0.65 |
| ▸ | RARA | P10276 | 8/20 | 0.65 |
| ▸ | RARB | P10826 | 8/20 | 0.65 |
| ▸ | RXRB | P28702 | 3/20 | 0.65 |
| ▸ | RXRG | P48443 | 3/20 | 0.65 |
| ▸ | PPARG | P37231 | 12/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8151971 | 1.00 | RXRA (0.65) | RXRARARGRARARARBRXRB | |
| SCHEMBL8146559 | 1.00 | RXRA (0.65) | RXRARARGRARARARBRXRB | |
| SCHEMBL8561873 | 0.90 | RXRA (0.62) | RXRARARGRARARARBRXRB | |
| SCHEMBL8561875 | 0.90 | RXRA (0.62) | RXRARARGRARARARBRXRB | |
| SCHEMBL8560229 | 0.86 | RXRA (0.58) | RXRARARGRARARARBRXRB | |
| SCHEMBL8560235 | 0.86 | RXRA (0.58) | RXRARARGRARARARBRXRB | |
| SCHEMBL8850686 | 0.82 | RXRA (0.74) | RXRARARGRARARARBRXRB | |
| SCHEMBL8850533 | 0.82 | RXRA (0.74) | RXRARARGRARARARBRXRB | |
| SCHEMBL8850692 | 0.82 | RXRA (0.74) | RXRARARGRARARARBRXRB | |
| SCHEMBL8850541 | 0.82 | RXRA (0.74) | RXRARARGRARARARBRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0800503-B1 | NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2000-05-10 | — | — | EP | claimed |
| US-5721103-A | SKIN DISORDERS; VISION DEFECTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1998-02-24 | — | — | US | claimed |
| WO-1996020913-A1 | NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | claimed |
| US-6083977-A | HAVING ACTIVITY FOR RETINOIC ACID RECEPTORS AND RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0800503-B1 | NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2000-05-10 | — | — | EP | disclosed |
| US-5721103-A | SKIN DISORDERS; VISION DEFECTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0800503-A1 | NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020913-A1 | NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |